{"id":5046,"date":"2025-06-24T04:53:18","date_gmt":"2025-06-24T03:53:18","guid":{"rendered":"https:\/\/cbmeds.in\/?p=5046"},"modified":"2025-06-24T04:53:20","modified_gmt":"2025-06-24T03:53:20","slug":"fda-approves-first-ever-twice-yearly-hiv-prevention-injection-a-new-era-in-global-health","status":"publish","type":"post","link":"https:\/\/cbmeds.in\/?p=5046","title":{"rendered":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--1024x1024.png\" alt=\"\" class=\"wp-image-5047\" srcset=\"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--1024x1024.png 1024w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--300x300.png 300w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--150x150.png 150w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--768x768.png 768w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--500x500.png 500w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv--100x100.png 100w, https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png 1080w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>In a groundbreaking step forward in the fight against HIV, the U.S. Food and Drug Administration (FDA) has approved <strong>Yeztugo (lenacapavir)<\/strong> \u2014 the <strong>first and only twice-yearly injection for HIV prevention<\/strong>. This historic decision, announced on <strong>June 18, 2025<\/strong>, marks a major milestone in medical innovation and public health strategy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\uddec What Is Yeztugo (Lenacapavir)?<\/h3>\n\n\n\n<p>Yeztugo, developed by <strong>Gilead Sciences<\/strong>, is a long-acting <strong>capsid inhibitor<\/strong> \u2014 a type of antiviral medication that disrupts the protective shell (capsid) of the HIV virus, preventing it from replicating. What makes it revolutionary is its <strong>biannual dosage<\/strong>: just <strong>one injection every six months<\/strong> can help protect individuals from contracting HIV.<\/p>\n\n\n\n<p>This is a radical departure from current prevention methods like daily oral PrEP (pre-exposure prophylaxis) pills such as <strong>Truvada<\/strong> or <strong>Descovy<\/strong>, and even longer-acting injectables like <strong>Apretude<\/strong>, which require administration every two months.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udcca How Effective Is It?<\/h3>\n\n\n\n<p>Clinical trials have shown <strong>astonishing results<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Over <strong>99.9% of participants remained HIV-negative<\/strong> during trials.<\/li>\n\n\n\n<li>No cases of HIV were reported in individuals who received Yeztugo as scheduled.<\/li>\n\n\n\n<li>It was well tolerated with minimal side effects.<\/li>\n<\/ul>\n\n\n\n<p>This level of efficacy places it among the most successful tools in the HIV prevention arsenal to date.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83c\udf0d Why This Matters<\/h3>\n\n\n\n<p>The approval of Yeztugo could be a <strong>game-changer<\/strong> for both individuals and global public health initiatives:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplifies prevention<\/strong>: No need to remember daily pills or bi-monthly shots.<\/li>\n\n\n\n<li><strong>Reduces stigma<\/strong>: Fewer clinic visits and less frequent medication may encourage more people to seek protection.<\/li>\n\n\n\n<li><strong>Helps high-risk populations<\/strong>: Especially beneficial for individuals with poor access to consistent healthcare or those who struggle with medication adherence.<\/li>\n\n\n\n<li><strong>Pushes us closer to ending HIV transmission<\/strong>: With widespread adoption, this could drastically reduce new infections.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udcb0 What About Cost and Accessibility?<\/h3>\n\n\n\n<p>Currently, Yeztugo is <strong>priced around $28,000 annually<\/strong> in the U.S., which raises critical concerns about <strong>accessibility<\/strong>, especially in lower-income countries and underserved communities.<\/p>\n\n\n\n<p>While <strong>Gilead Sciences<\/strong> is working on insurance partnerships and patient-assistance programmes, many public health advocates are calling for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Global price negotiations<\/li>\n\n\n\n<li>Subsidized access in developing countries<\/li>\n\n\n\n<li>Stronger distribution frameworks<\/li>\n\n\n\n<li>International health agency support for rollout<\/li>\n<\/ul>\n\n\n\n<p>The World Health Organization (WHO) and UNAIDS are expected to weigh in as countries begin evaluating how Yeztugo fits into their national HIV prevention strategies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83d\udde3 Expert Reactions<\/h3>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThis is the kind of innovation we\u2019ve been waiting for. Twice-yearly PrEP can transform adherence, improve outcomes, and save lives.\u201d<br>\u2014 <em>Dr. Anthony Fauci, Former NIAID Director<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThis approval represents not just a scientific victory, but a public health triumph. The fewer barriers to prevention, the better our chances at ending the epidemic.\u201d<br>\u2014 <em>UNAIDS spokesperson<\/em><\/p>\n<\/blockquote>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">\ud83e\udded The Road Ahead<\/h3>\n\n\n\n<p>While Yeztugo is a tremendous breakthrough, <strong>science alone isn\u2019t enough<\/strong>. Equitable access, education, community trust, and continued investment will be essential to ensure this powerful tool reaches those who need it most.<\/p>\n\n\n\n<p>As we look toward a future where HIV may no longer be a public health threat, innovations like Yeztugo give us hope \u2014 not just for treatment, but for <strong>prevention<\/strong>, dignity, and global progress.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">\ud83d\udcac Final Thoughts<\/h2>\n\n\n\n<p>Yeztugo is more than a drug \u2014 it\u2019s a symbol of progress. A vision of what\u2019s possible when science, advocacy, and compassion come together. If we rise to the challenge of making it accessible, we may be witnessing the beginning of the end for one of the world\u2019s most enduring epidemics.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>Stay informed. Stay protected. The future of HIV prevention has arrived.<\/strong><br><em>Learn more about PrEP options and HIV care at <a class=\"\" href=\"https:\/\/cbmeds.in\">cbmeds.in<\/a><\/em><\/p>\n\n\n\n<p>#HIVPrevention #Yeztugo #Lenacapavir #FDAApproved #PublicHealthBreakthrough #MedicalInnovation #TwiceAYearShot #EndHIV #cbmeds #GlobalHealth #HealthEquity<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a groundbreaking step forward in the fight against HIV, the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) \u2014 the first and only twice-yearly injection for HIV prevention. This historic decision, announced on June 18, 2025, marks a major milestone in medical innovation and public health strategy. \ud83e\uddec What Is Yeztugo (Lenacapavir)? [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cbmeds.in\/?p=5046\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech\" \/>\n<meta property=\"og:description\" content=\"In a groundbreaking step forward in the fight against HIV, the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) \u2014 the first and only twice-yearly injection for HIV prevention. This historic decision, announced on June 18, 2025, marks a major milestone in medical innovation and public health strategy. \ud83e\uddec What Is Yeztugo (Lenacapavir)? [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cbmeds.in\/?p=5046\" \/>\n<meta property=\"og:site_name\" content=\"Curiance Biotech\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T03:53:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T03:53:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/person\\\/4e7dce38d197111ae0c614cbeef78e85\"},\"headline\":\"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health\",\"datePublished\":\"2025-06-24T03:53:18+00:00\",\"dateModified\":\"2025-06-24T03:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046\"},\"wordCount\":588,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/hiv-.png\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cbmeds.in\\\/?p=5046#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046\",\"name\":\"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/hiv-.png\",\"datePublished\":\"2025-06-24T03:53:18+00:00\",\"dateModified\":\"2025-06-24T03:53:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cbmeds.in\\\/?p=5046\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#primaryimage\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/hiv-.png\",\"contentUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/hiv-.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?p=5046#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cbmeds.in\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#website\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/\",\"name\":\"cbmeds.in\",\"description\":\"Tomorrow&#039;s Medicine Today\",\"publisher\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#organization\"},\"alternateName\":\"Curiance Biotech\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cbmeds.in\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#organization\",\"name\":\"CB Meds\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Logo-1-1-1.png\",\"contentUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Logo-1-1-1.png\",\"width\":640,\"height\":640,\"caption\":\"CB Meds\"},\"image\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/person\\\/4e7dce38d197111ae0c614cbeef78e85\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"url\":\"https:\\\/\\\/cbmeds.in\\\/?author=2\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cbmeds.in\/?p=5046","og_locale":"en_US","og_type":"article","og_title":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech","og_description":"In a groundbreaking step forward in the fight against HIV, the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) \u2014 the first and only twice-yearly injection for HIV prevention. This historic decision, announced on June 18, 2025, marks a major milestone in medical innovation and public health strategy. \ud83e\uddec What Is Yeztugo (Lenacapavir)? [&hellip;]","og_url":"https:\/\/cbmeds.in\/?p=5046","og_site_name":"Curiance Biotech","article_published_time":"2025-06-24T03:53:18+00:00","article_modified_time":"2025-06-24T03:53:20+00:00","og_image":[{"width":1080,"height":1080,"url":"http:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png","type":"image\/png"}],"author":"Admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cbmeds.in\/?p=5046#article","isPartOf":{"@id":"https:\/\/cbmeds.in\/?p=5046"},"author":{"name":"Admin","@id":"https:\/\/cbmeds.in\/#\/schema\/person\/4e7dce38d197111ae0c614cbeef78e85"},"headline":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health","datePublished":"2025-06-24T03:53:18+00:00","dateModified":"2025-06-24T03:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/cbmeds.in\/?p=5046"},"wordCount":588,"commentCount":0,"publisher":{"@id":"https:\/\/cbmeds.in\/#organization"},"image":{"@id":"https:\/\/cbmeds.in\/?p=5046#primaryimage"},"thumbnailUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cbmeds.in\/?p=5046#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cbmeds.in\/?p=5046","url":"https:\/\/cbmeds.in\/?p=5046","name":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health - Curiance Biotech","isPartOf":{"@id":"https:\/\/cbmeds.in\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cbmeds.in\/?p=5046#primaryimage"},"image":{"@id":"https:\/\/cbmeds.in\/?p=5046#primaryimage"},"thumbnailUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png","datePublished":"2025-06-24T03:53:18+00:00","dateModified":"2025-06-24T03:53:20+00:00","breadcrumb":{"@id":"https:\/\/cbmeds.in\/?p=5046#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cbmeds.in\/?p=5046"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cbmeds.in\/?p=5046#primaryimage","url":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png","contentUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/hiv-.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/cbmeds.in\/?p=5046#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cbmeds.in\/"},{"@type":"ListItem","position":2,"name":"FDA Approves First-Ever Twice-Yearly HIV Prevention Injection: A New Era in Global Health"}]},{"@type":"WebSite","@id":"https:\/\/cbmeds.in\/#website","url":"https:\/\/cbmeds.in\/","name":"cbmeds.in","description":"Tomorrow&#039;s Medicine Today","publisher":{"@id":"https:\/\/cbmeds.in\/#organization"},"alternateName":"Curiance Biotech","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cbmeds.in\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cbmeds.in\/#organization","name":"CB Meds","url":"https:\/\/cbmeds.in\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cbmeds.in\/#\/schema\/logo\/image\/","url":"https:\/\/cbmeds.in\/wp-content\/uploads\/2023\/09\/Logo-1-1-1.png","contentUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2023\/09\/Logo-1-1-1.png","width":640,"height":640,"caption":"CB Meds"},"image":{"@id":"https:\/\/cbmeds.in\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cbmeds.in\/#\/schema\/person\/4e7dce38d197111ae0c614cbeef78e85","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/15fd88a826785cafc6f8817a828358e8c21fe40ba0e884a6b4c496258f3bfcf1?s=96&d=mm&r=g","caption":"Admin"},"url":"https:\/\/cbmeds.in\/?author=2"}]}},"_links":{"self":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/posts\/5046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5046"}],"version-history":[{"count":1,"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/posts\/5046\/revisions"}],"predecessor-version":[{"id":5048,"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/posts\/5046\/revisions\/5048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/media\/5047"}],"wp:attachment":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}